학회소개 
 |
정준호(서울대학교)
Dr. Junho Chung graduated from Seoul National University, College of Medicine and received his M.D. degree. After his graduation, he joined a dual degree program at Department of Biochemistry and Molecular Biology of the same college and obtained his Ph. D. degree under the supervision of Prof. Hong-Keun Chung. Then he joined the late Dr. Carlos F. Barbas III’s laboratory at Scripps Research, La Jolla, CA, USA as a research associate, who is one of the pioneers in the field of recombinant antibody engineering. From 2000, he has been a faculty of Seoul National University, College of Medicine at the Department of Biochemistry and Molecular Biology. Most of his research has been focused on antibody engineering. He published more than 140 articles in the field and invented more than 30 registered patents. Until now, more than 20 patents have been licensed to biotech companies. Several antibodies from his laboratory are either in clinical or preclinical development: an anti-hepatocyte growth factor antibody under phase II clinical trial (NCT04368507), an anti-FAM19A5 antibody under phase I clinical trial (NCT05143463), and an anti-CD19 CAR T with a novel anti-CD19 scFv under phase I clinical trial (NCT053338931). In preclinical development, there are an anti-complement C5 antibody (ImmuneAbs and Samsung Biologics), an antibody for Severe Fever with Thrombocytopenia Syndrome (a localized viral infective disease among China, Korea, Japan and east Asia) and one chimeric antigen receptor T cell therapy. Recently, he broadened his research area with a heavy focus on the analysis of B cell receptor (BCR) repertoire using machine-learning algorithm. Facing COVID-19 epidemic, he and his colleagues analyzed the patients’ repertoire and discovered stereotypic neutralizing antibodies, which frequently pre-exist among naive population. Representative papers |